

# Inhalation Sciences



## PRESS RELEASE

Published: 23-08-2019

## Inhalation Sciences receives new order worth 1.8 MSEK

(Stockholm August 23 2019) **Inhalation Sciences Sweden AB has received an order for a new PreciseInhale system from an existing customer with global lab facilities. The new order includes a range of exposure modules and PreciseInhale's new customized nebulizer feature.**

CEO Lena Heffler: "I'm pleased to see this trend of existing customers returning to purchase a second instrument from ISAB. It speaks volumes about the quality of data, range of capabilities and important competitive edge PreciseInhale gives them".

ISAB's PreciseInhale aerosol generator generates accurate *in vivo* and *ex vivo* data, from nebulized solutions as well as commercial dry powder inhalers. The new purchase includes ISAB's new integrated nebulizer feature, which the company launched in [February 2019](#).

CEO Lena Heffler: "This sale is a clear indication of the scientific and strategic value PreciseInhale gives companies—enabling them to generate more accurate data, minimize risk and accelerate research. We're delighted with our customers' confidence in our technology's capabilities."

### **For more information about Inhalation Sciences, please contact:**

Lena Heffler, CEO  
E-mail: [lena.heffler@inhalation.se](mailto:lena.heffler@inhalation.se)  
Telephone: +46 (0)70 205 9620

### **About Inhalations Sciences Sweden AB (publ)**

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company's patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we inhale them.

***The information above was provided by Inhalation Sciences AB according to EU Market Abuse Regulations. The information was provided, through the agency of the contact person above, for publication on August 23, 2019.***

